These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8764886)

  • 1. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC).
    Zimmermann J; Caravatti G; Mett H; Meyer T; Müller M; Lydon NB; Fabbro D
    Arch Pharm (Weinheim); 1996 Jul; 329(7):371-6. PubMed ID: 8764886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
    J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
    J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
    Salerno S; García-Argáez AN; Barresi E; Taliani S; Simorini F; La Motta C; Amendola G; Tomassi S; Cosconati S; Novellino E; Da Settimo F; Marini AM; Via LD
    Eur J Med Chem; 2018 Apr; 150():446-456. PubMed ID: 29547832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes.
    Gschwendt M; Dieterich S; Rennecke J; Kittstein W; Mueller HJ; Johannes FJ
    FEBS Lett; 1996 Aug; 392(2):77-80. PubMed ID: 8772178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta.
    Jirousek MR; Gillig JR; Gonzalez CM; Heath WF; McDonald JH; Neel DA; Rito CJ; Singh U; Stramm LE; Melikian-Badalian A; Baevsky M; Ballas LM; Hall SE; Winneroski LL; Faul MM
    J Med Chem; 1996 Jul; 39(14):2664-71. PubMed ID: 8709095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.
    Kraker AJ; Hartl BG; Amar AM; Barvian MR; Showalter HD; Moore CW
    Biochem Pharmacol; 2000 Oct; 60(7):885-98. PubMed ID: 10974196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.
    Courage C; Budworth J; Gescher A
    Br J Cancer; 1995 Apr; 71(4):697-704. PubMed ID: 7710931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Anilino-pyrimidine, novel aldosterone synthase (CYP11B2) inhibitors bearing pyrimidine structures.
    Meguro M; Miyauchi S; Kanao Y; Naito S; Suzuki K; Inoue S; Yamada K; Homma T; Chiba K; Nara F; Furuzono S
    Bioorg Med Chem Lett; 2017 May; 27(9):1902-1906. PubMed ID: 28359792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKCdelta and discovery of an ILV analogue of improved isozyme selectivity.
    Kozikowski AP; Wang S; Ma D; Yao J; Ahmad S; Glazer RI; Bogi K; Acs P; Modarres S; Lewin NE; Blumberg PM
    J Med Chem; 1997 Apr; 40(9):1316-26. PubMed ID: 9135029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of novel condensed pyrrolo[1,2-c]pyrimidines featuring morpholine moiety as PI3Kα inhibitors.
    Ibrahim MA; Abou-Seri SM; Hanna MM; Abdalla MM; El Sayed NA
    Eur J Med Chem; 2015 Jun; 99():1-13. PubMed ID: 26037808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potent and selective PKC-theta inhibitors.
    Cywin CL; Dahmann G; Prokopowicz AS; Young ER; Magolda RL; Cardozo MG; Cogan DA; Disalvo D; Ginn JD; Kashem MA; Wolak JP; Homon CA; Farrell TM; Grbic H; Hu H; Kaplita PV; Liu LH; Spero DM; Jeanfavre DD; O'Shea KM; White DM; Woska JR; Brown ML
    Bioorg Med Chem Lett; 2007 Jan; 17(1):225-30. PubMed ID: 17055721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
    Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
    Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct evidence of cytoplasmic delivery of PKC-alpha, -epsilon and -zeta pseudosubstrate lipopeptides: study of their implication in the induction of apoptosis.
    Thiam K; Loing E; Zoukhri D; Rommens C; Hodges R; Dartt D; Verwaerde C; Auriault C; Gras-Masse H; Sergheraert C
    FEBS Lett; 1999 Oct; 459(3):285-90. PubMed ID: 10526151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic analysis of protein kinase C inhibition by staurosporine: evidence that inhibition entails inhibitor binding at a conserved region of the catalytic domain but not competition with substrates.
    Ward NE; O'Brian CA
    Mol Pharmacol; 1992 Feb; 41(2):387-92. PubMed ID: 1538715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway.
    Chen CC; Sun YT; Chen JJ; Chiu KT
    J Immunol; 2000 Sep; 165(5):2719-28. PubMed ID: 10946303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential for isoenzyme-selective modulation of protein kinase C.
    Hofmann J
    FASEB J; 1997 Jul; 11(8):649-69. PubMed ID: 9240967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation and substrate specificity of the human protein kinase C alpha and zeta isoenzymes.
    Kochs G; Hummel R; Meyer D; Hug H; Marmé D; Sarre TF
    Eur J Biochem; 1993 Sep; 216(2):597-606. PubMed ID: 8375396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism.
    Stewart JR; Ward NE; Ioannides CG; O'Brian CA
    Biochemistry; 1999 Oct; 38(40):13244-51. PubMed ID: 10529197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.